Published online Dec 27, 2014. doi: 10.4254/wjh.v6.i12.836
Revised: September 30, 2014
Accepted: October 28, 2014
Published online: December 27, 2014
Processing time: 135 Days and 2.2 Hours
As a result of donor shortage and high postoperative morbidity and mortality after liver transplantation, hepatectomy is the most widely applicable and reliable option for curative treatment of hepatocellular carcinoma (HCC). Because intrahepatic tumor recurrence is frequent after loco-regional therapy, repeated treatments are advocated provided background liver function is maintained. Among treatments including local ablation and transarterial chemoembolization, hepatectomy provides the best long-term outcomes, but studies comparing hepatectomy with other nonsurgical treatments require careful review for selection bias. In patients with initially unresectable HCC, transarterial chemo-or radio-embolization, and/or systemic chemotherapy can down-stage the tumor and conversion to resectable HCC is achieved in approximately 20% of patients. However, complete response is rare, and salvage hepatectomy is essential to help prolong patients’ survival. To counter the short recurrence-free survival, excellent overall survival is obtained by combining and repeating different treatments. It is important to recognize hepatectomy as a complement, rather than a contraindication, to other nonsurgical treatments in a multidisciplinary approach for patients with HCC, including recurrent or unresectable tumors.
Core tip: Previous studies comparing hepatectomy with other nonsurgical treatments for hepatocellular carcinoma (HCC) evaluated which provided superior survival benefit. However, considering the high recurrence rate after curative loco-regional treatment, and limited indications for hepatectomy because of background liver damage, it is important to recognize hepatectomy as a complement to other nonsurgical treatment, rather than a contraindication. A multidisciplinary approach combining and repeating different treatments prolongs patients’ survival with HCC, including those with recurrent or initially unresectable tumors.